80
Participants
Start Date
March 20, 2017
Primary Completion Date
November 8, 2018
Study Completion Date
November 25, 2019
Apremilast
Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
Placebo
Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
CHU de Nice - Dermatologie - Hôpital Archet, Nice
Centre Hospitalier Universitaire de Nice
OTHER